Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.46 |
| ▸ | MMP3 | P08254 | 9/20 | 0.46 |
| ▸ | MMP9 | P14780 | 5/20 | 0.45 |
| ▸ | MMP14 | P50281 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 5/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexylamine SCHEMBL6137314 | 1.00 | MMP2 (0.46) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL6137313 | 0.90 | MMP2 (0.53) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL6137316 | 0.90 | MMP2 (0.53) | MMP2MMP3MMP9MMP14MMP13 | |
| Cyclohexylamine SCHEMBL5408739 | 0.86 | MMP2 (0.46) | MMP2MMP3MMP1PPARG | |
| Cyclohexylamine SCHEMBL5408733 | 0.86 | MMP2 (0.46) | MMP2MMP3MMP1PPARG | |
| SCHEMBL6137315 | 0.84 | MMP2 (0.46) | MMP2MMP3MMP9MMP14MMP13 | |
| Cyclohexylamine SCHEMBL6137474 | 0.78 | PPARG (0.37) | MMP2MMP3MMP9MMP14MMP13 | |
| Cyclohexylamine SCHEMBL6137479 | 0.78 | PPARG (0.37) | MMP2MMP3MMP9MMP14MMP13 | |
| SCHEMBL5400156 | 0.74 | GRIK1 (0.54) | MMP2MMP3MMP9MMP14MMP1 | |
| SCHEMBL5400150 | 0.74 | GRIK1 (0.54) | MMP2MMP3MMP9MMP14MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1199301-B1 | Olefination process to itaconate and succinate derivatives | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6750363-B2 | Olefination process to itaconate and succinate derivatives | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020188121-A1 | Novel olefination process to itaconate and succinate derivatives | DERRICK ANDREW MICHAEL (GB) | 2002-12-12 | — | — | US | disclosed |
| US-6452041-B1 | REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| EP-1199301-A1 | Olefination process to itaconate and succinate derivatives | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188121-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, OGDH, HADHA | MMP2 3089/4885MMP3 3048/4885MMP9 3859/4885 |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, HADHA, OGDH | MMP2 2827/4885MMP3 3007/4885MMP9 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.